Inhibition of PI3K/mTOR Overcomes Nilotinib Resistance in BCR-ABL1 Positive Leukemia Cells through Translational Down-Regulation of MDM2

Overview of attention for article published in PLOS ONE, December 2013

Altmetric Badge

Mentioned by

patent: 1 patent

Citations

dimensions_citation: 39 Dimensions

Readers on

mendeley: 25 Mendeley

Summary Patents Dimensions citations

So far, Dimensions has found 39 publications that cite this research output.

39

The most recent citing publications are shown below. View all 39 publications that cite this research output on Dimensions.

The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia

Article in Pathology - Research and Practice (January 2024)

BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia

Article in Pharmaceutics (January 2022)

CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells

Article in Biochemical Pharmacology (June 2021)